Clinical characteristics associated with bone mineral density improvement after 1-year alendronate/vitamin d3 or calcitriol treatment
| Autor: | Liao, Er-Yuan, Zhang, Zhen-Lin, Xia, Wei-Bo, Lin, Hua, Cheng, Qun, Wang, Li, Hao, Yong-Qiang, Chen, De-Cai, Tang, Hai, Peng, Yong-De, You, Li, He, Liang, Hu, Zhao-Heng, Song, Chun-Li, Wei, Fang, Wang, Jue, Zhang, Lei |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
calcitriol
China Lumbar Vertebrae Time Factors Alendronate Bone Density Conservation Agents Observational Study Middle Aged postmenopausal osteoporosis alendronate sodium Treatment Outcome Bone Density bone turnover biomarker Dietary Supplements ComputingMethodologies_DOCUMENTANDTEXTPROCESSING Humans Female bone mineral density post hoc analysis Osteoporosis Postmenopausal Research Article Aged Cholecalciferol |
| Zdroj: | Medicine |
| ISSN: | 1536-5964 0025-7974 |
| Popis: | Supplemental Digital Content is available in the text Baseline and on-treatment characteristics, including age, obesity, calcium intake, and bone turnover markers, may predict the bone mineral density (BMD) response in women with postmenopausal osteoporosis (PMO) to 1 to 2 years of antiresorptive therapy and/or vitamin D supplementation. This study aimed to explore clinical characteristics associated with 12-month BMD improvement in Chinese women with postmenopausal osteoporosis (PMO). In this post hoc analysis of a previous phase 3 multicenter, randomized controlled trial, Chinese PMO women who were treated with once weekly alendronate 70 mg/vitamin D3 5600 IU (ALN/D5600) or once daily calcitriol 0.25 mcg, and had measurements of 1-year lumbar spine BMD (LS-BMD) and on-treatment bone turnover markers (BTMs) were included in the analysis. In Chinese PMO patients on ALN/D5600, 1-year LS-BMD change was negatively correlated with age (β = −0.00084, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|